PCP stays on federal and workplace drug test panels because it is one of the original five drug classes named in SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs, screened at a 25 ng/mL urine immunoassay cutoff and confirmed at the same 25 ng/mL threshold. The Department of Health and Human Services reaffirmed this panel, unchanged, in its most recent authorized testing panel notice in the Federal Register. Even though phencyclidine use is far less common nationally than it was decades ago, the substance is concentrated in specific regions, carries severe safety risk when it does appear, and remains locked into the federal panel structure that DOT-regulated and many non-DOT employer programs are built around.
This article explains where PCP fits in the "federal five," how the cutoff and confirmation process works, why prevalence data has not been enough to remove it from panels, how long it is detectable, and what the published literature says about substances that can cross-react on a PCP immunoassay.
PCP and the Federal Five: What SAMHSA's Mandatory Guidelines Actually Require
Federal workplace drug testing programs, and by extension the transportation industry testing required under DOT rules, are built on a specific, named list of drug classes rather than an open-ended "test for drugs" standard. That list, historically called the federal five, is marijuana, cocaine, opiates, phencyclidine, and amphetamines.1 HHS is required to publish the authorized drug testing panel and its cutoffs in the Federal Register each year under Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Urine.1 The most recent notice, published March 13, 2026, states plainly that the department "made no revisions to the current drug testing panels for both urine and oral fluid," meaning PCP's place on the panel is not an oversight or legacy artifact quietly waiting to be phased out. It was reviewed and reaffirmed as recently as this year.1
Because DOT-regulated safety-sensitive testing (commercial driving, aviation, rail, transit, pipeline, and maritime) is required to use HHS-certified laboratories and the same federally authorized panel, PCP is not an optional add-on that a transportation employer can drop from its program. It is baked into the standardized panel structure the whole system runs on.
The 25 ng/mL Cutoff, Initial and Confirmatory
The current HHS Drug Testing Panel for urine sets the phencyclidine cutoff at 25 ng/mL for the initial immunoassay screen and 25 ng/mL for the confirmatory test, the same threshold used at both stages.1 For oral fluid testing, the cutoff is lower, 10 ng/mL at both the initial and confirmatory stage.1 Compared with the other federal five substances, PCP's urine cutoff is notably low, which reflects how potent the drug is in small doses relative to substances like the opiates or amphetamines, which are set at hundreds or thousands of nanograms per milliliter.
| Federal Five Substance | Initial (Screening) Cutoff, Urine | Confirmatory Cutoff, Urine |
|---|---|---|
| Marijuana metabolite (THCC) | 50 ng/mL | 15 ng/mL |
| Cocaine metabolite (benzoylecgonine) | 150 ng/mL | 100 ng/mL |
| Opiates (codeine/morphine) | 2,000 ng/mL | 2,000 ng/mL (codeine), 4,000 ng/mL (morphine) |
| Phencyclidine (PCP) | 25 ng/mL | 25 ng/mL |
| Amphetamine/methamphetamine | 500 ng/mL | 250 ng/mL each |
Source: HHS Drug Testing Panel, Federal Register notice, March 13, 2026.1
Why PCP Stays on the Panel Despite Lower National Prevalence
PCP is genuinely a smaller share of national drug use than it was during its peak in the 1970s. DEA's own fact sheet on phencyclidine notes that lifetime and past-year use figures from the National Survey on Drug Use and Health have stayed low and fairly flat for years, with past-year illicit use consistently under one tenth of one percent of the population aged 12 and older through 2024, and past-year use among 12th graders in the national Monitoring the Future survey ranging between roughly 0.5 percent and 1.2 percent from 2021 through 2025, never rising above 2 percent in over two decades.2
Three things keep PCP on the panel anyway. First, use is not evenly distributed. DEA's fact sheet describes PCP distribution and use as "localized to select metropolitan areas," meaning national averages can mask real regional spikes that matter to employers, correctional facilities, and treatment programs operating in an affected area.2 DEA's National Forensic Laboratory Information System also shows year over year lab submissions moving both down and up in recent years rather than trending steadily toward zero.2 Second, the safety consequence of a missed PCP-impaired employee is severe. PCP is associated with agitation, psychosis, and unpredictable behavior, exactly the profile a safety-sensitive employer, correctional facility, or treatment program cannot afford to screen out just because it is statistically less common than marijuana or opiates.2 Third, federal alignment matters operationally. Because DOT and many federal-contractor programs are required to use the HHS-authorized panel as a single standardized unit, removing one substance would require a rulemaking change to the Mandatory Guidelines themselves, and HHS has repeatedly reaffirmed the current panel without changes.1
How Long PCP Is Detectable
PCP has a long elimination half-life, and detection windows in urine vary with dose, frequency of use, and individual metabolism. Single, occasional use is generally detectable in urine for several days after last use, while chronic, heavy use can extend the detection window considerably longer because PCP accumulates in fat tissue and is released slowly over time. This variability is one more reason a documented, defensible cutoff and confirmation process matters more than any single detection-window estimate, since the presence of PCP in a specimen at or above the panel cutoff indicates recent exposure, not a precise timeline of use.
False Positives: What the Published Literature Documents
Immunoassay screening works by detecting antibody binding to a class of structurally related molecules, not by identifying an exact compound, which is the mechanism behind every documented cross-reactivity issue on every drug panel, PCP included. Published clinical literature has documented several medications capable of producing a false-positive PCP immunoassay result that does not hold up on confirmation. A study indexed by the National Library of Medicine examining false-positive phencyclidine urine screens found that common, legitimately prescribed or over-the-counter medications, including the cough suppressant dextromethorphan, the analgesic tramadol, and the antihistamine diphenhydramine, were associated with unconfirmed PCP-positive immunoassay results in a meaningful share of cases that failed to confirm by GC-MS.3 A separate peer-reviewed case report archived by the National Library of Medicine documented a false-positive PCP result on an 11-panel urine drug screen in a patient on long-term venlafaxine, an antidepressant, illustrating that cross-reactivity is not limited to a single drug class.4 Ketamine, which is chemically related to PCP as a fellow arylcyclohexylamine, has also been reported in the literature as a cross-reactant on some PCP immunoassays.
None of these substances will confirm as phencyclidine on a proper laboratory confirmation test, because confirmation identifies the exact molecule present rather than a class of similarly shaped molecules. This is exactly why a non-negative PCP screen is a presumptive result, not a final one.
Confirmation Testing Resolves Every Non-Negative Screen
A non-negative immunoassay result for PCP, whether from a point-of-collection cup, dip card, or laboratory-based screen, must be sent for laboratory confirmation, typically by gas chromatography-mass spectrometry, before it is treated as a final result. Confirmation testing identifies and quantifies the specific molecule present, which is what separates a genuine PCP-positive specimen from one flagged because of dextromethorphan, tramadol, diphenhydramine, venlafaxine, or another structurally similar compound. Confirmed non-negative results should then be reviewed by a Medical Review Officer or an equivalent qualified reviewer, who can consider a donor's documented, legitimate medical explanation before any result is reported to an employer.
Building a Panel That Still Covers PCP
Employers, clinics, correctional facilities, and treatment programs that want federal-panel alignment need a testing product that still includes PCP rather than a stripped-down panel built around only the highest-volume substances. ASC's multi-panel drug testing cups and urine drug test dip cards are built to include PCP alongside the rest of the federal five, which matters for DOT-regulated transportation testing and broader workplace drug testing programs staying aligned with the federally authorized panel. Buyers sourcing broadly across drug of abuse test kits should confirm PCP is listed among the target analytes, and programs resolving non-negative screens should have a documented path to a certified lab, supported by ASC's laboratory testing supplies, rather than reporting a presumptive screen as final.
Medical and Legal Disclaimer
Drug test screening devices, including PCP panels, provide preliminary, presumptive results only and do not diagnose drug dependency or confirm a specific individual's use. Any non-negative screening result must be sent to a certified laboratory for confirmation using a method such as GC-MS before it is treated as final, and confirmed non-negative results should be reviewed by a qualified Medical Review Officer or equivalent reviewer before any employment, clinical, or legal action is taken. This article is written for general educational purposes for testing program administrators and buyers. It is not medical advice, legal advice, or a substitute for consulting a physician, MRO, laboratory toxicologist, or qualified employment counsel about a specific case.
Frequently Asked Questions
Why does SAMHSA still require PCP testing when so few people use it?
PCP remains one of the five drug classes named in SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs, and HHS reaffirmed the current panel, including PCP, without revision in its most recent Federal Register notice. National use is low and use is concentrated in specific metropolitan areas, but the safety risk from an undetected PCP-impaired individual in a safety-sensitive role is severe enough that the substance has stayed on the federally required panel.
What is the cutoff level for a PCP urine drug test?
The current HHS Drug Testing Panel sets the phencyclidine cutoff at 25 ng/mL for the initial immunoassay screen and 25 ng/mL for the confirmatory laboratory test in urine. Oral fluid testing uses a lower cutoff of 10 ng/mL at both stages.
Can medications cause a false positive PCP result?
Yes. Published literature has documented false-positive PCP immunoassay results associated with dextromethorphan, tramadol, diphenhydramine, and venlafaxine, and ketamine has also been reported as a cross-reactant because of its structural similarity to PCP. None of these substances will confirm as phencyclidine on a proper GC-MS laboratory confirmation test, which is why non-negative screens are never treated as final results.
How long does PCP stay detectable in urine?
Detection windows vary with dose, frequency of use, and individual metabolism. Occasional, single use is generally detectable for several days, while chronic, heavy use can extend the window considerably longer because PCP accumulates in fat tissue and is released slowly. A positive screening result indicates recent exposure at or above the panel cutoff, not a precise timeline of use.
